Vertex Pharmaceuticals Incorporated to Post Q3 2025 Earnings of $3.74 Per Share, Zacks Research Forecasts (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Research analysts at Zacks Research cut their Q3 2025 EPS estimates for shares of Vertex Pharmaceuticals in a note issued to investors on Friday, April 19th. Zacks Research analyst R. Department now forecasts that the pharmaceutical company will post earnings of $3.74 per share for the quarter, down from their previous forecast of $3.75. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $14.95 per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q1 2026 earnings at $3.77 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. The firm had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same quarter in the previous year, the business earned $3.33 earnings per share.

A number of other research analysts have also recently weighed in on the stock. Barclays lifted their price target on shares of Vertex Pharmaceuticals from $446.00 to $472.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Wells Fargo & Company upped their price target on shares of Vertex Pharmaceuticals from $500.00 to $540.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Robert W. Baird lowered Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price objective on the stock. in a research report on Wednesday, January 31st. Royal Bank of Canada upped their target price on Vertex Pharmaceuticals from $397.00 to $420.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 6th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $500.00 target price on shares of Vertex Pharmaceuticals in a research note on Monday, April 15th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $429.45.

Vertex Pharmaceuticals Stock Up 1.4 %

Shares of NASDAQ:VRTX opened at $399.92 on Monday. The stock has a 50-day simple moving average of $413.23 and a 200-day simple moving average of $398.05. The stock has a market capitalization of $103.36 billion, a P/E ratio of 28.79, a PEG ratio of 1.86 and a beta of 0.35. Vertex Pharmaceuticals has a 1 year low of $316.43 and a 1 year high of $448.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99.

Insiders Place Their Bets

In related news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the transaction, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at $23,755,762.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the transaction, the executive vice president now owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Amit Sachdev sold 3,222 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The disclosure for this sale can be found here. Insiders sold 12,381 shares of company stock worth $5,203,249 over the last ninety days. Company insiders own 0.20% of the company’s stock.

Institutional Trading of Vertex Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. CWM LLC boosted its position in Vertex Pharmaceuticals by 17.6% during the 3rd quarter. CWM LLC now owns 5,375 shares of the pharmaceutical company’s stock worth $1,869,000 after acquiring an additional 806 shares during the period. Geneos Wealth Management Inc. grew its position in Vertex Pharmaceuticals by 39.4% during the third quarter. Geneos Wealth Management Inc. now owns 191 shares of the pharmaceutical company’s stock valued at $66,000 after purchasing an additional 54 shares in the last quarter. Global Retirement Partners LLC increased its stake in Vertex Pharmaceuticals by 28.4% in the 3rd quarter. Global Retirement Partners LLC now owns 1,194 shares of the pharmaceutical company’s stock valued at $421,000 after buying an additional 264 shares during the period. HB Wealth Management LLC increased its stake in Vertex Pharmaceuticals by 48.2% in the 3rd quarter. HB Wealth Management LLC now owns 3,626 shares of the pharmaceutical company’s stock valued at $1,261,000 after buying an additional 1,180 shares during the period. Finally, First Affirmative Financial Network lifted its position in Vertex Pharmaceuticals by 21.9% in the 3rd quarter. First Affirmative Financial Network now owns 736 shares of the pharmaceutical company’s stock worth $256,000 after buying an additional 132 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.